Navigation Links
Cardium's InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
Date:6/19/2008

ch as recurrent angina. For more information about Cardium and its businesses, products and therapeutic candidates, please visit http://www.cardiumthx.com or view its 2007 Annual Report at http://www.cardiumthx.com/flash/pdf/CardiumAR07_Book_FINAL.pdf.

Cardium's InnerCool Therapies subsidiary is a San Diego-based medical technology company in the emerging field of patient temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or stroke, and to potentially lessen or prevent associated injuries such as adverse neurological outcomes. For more information about Cardium's InnerCool subsidiary and patient temperature modulation, including InnerCool's Celsius Control System(TM) and CoolBlue System(TM), please visit http://www.innercool.com.

Cardium's Tissue Repair Company subsidiary (TRC) is a San Diego-based biopharmaceutical company focused on the development of growth factor therapeutics for the treatment of severe chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate is initially being developed to be administered once or twice for the potential treatment of non-healing diabetic foot ulcers. Other potential applications for TRC's Gene Activated Matrix(TM) (GAM(TM)) technology include therapeutic angiogenesis (cardiovascular ischemia, peripheral arterial disease) and orthopedic products, including hard tissue (bone) and soft tissue (ligament, tendon, cartilage) repair. For more information about Cardium's Tissue Repair Company subsidiary, please visit

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
2. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
3. Intra-Cellular Therapies Provides Overview of its Proprietary Portfolio of Compounds for the Treatment of Female Sexual Dysfunction (FSD)
4. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
5. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
6. Fate Therapeutics Created by Leading Stem Cell Scientists to Pursue New Approaches to Stem Cell Therapies
7. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
8. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
9. Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
10. Teva Pharmaceuticals Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis
11. CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... medical research executives, scientists, policy makers, and funders today ... strategies at the inaugural Partnering for Cures ... of the Milken Institute, convened Partnering for Cures ... scientific discovery into an accessible therapy. This effort ...
(Date:12/2/2009)... Gabon, December 2 , ... and Heritage" , Coinciding ... 2010 the,Gabonese Republic is hosting an international conference ... resources in Africa. The,conference will be attended by ...
(Date:12/2/2009)... 2 S*BIO Pte Ltd today announced data presentations ... American Society of Hematology 51st Annual Meeting and Exposition ... the clinical results from the Phase 1 dose-escalation trial ... profile in dose levels ranging from 100 to 600 ...
(Date:12/2/2009)... -- The world is going through,extraordinary times; markets are ... industries. It turns out that the pharma industry has ... take a,vacation. , During the ... Johnson & Johnson inaugurated an R&D center in Shanghai, ...
Breaking Biology Technology:Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3
... industry in the Northeast featured on Hotbed ... BioSpace, the world,s leading,online bioscience job board ... morning the 2008-2009 Pharm Country(TM) Hotbed Campaign ... New Jersey, and Pennsylvania., (Photo: ...
... NEBIDO Delay, LEXINGTON, Mass., June 30 Indevus,Pharmaceuticals, ... has received,an approvable letter from the U.S. Food and ... Application (NDA) submitted to the FDA in,August 2007. The ... may be approved if the Company is able to ...
... On June 25, 2008,Alseres Pharmaceuticals, Inc. (Nasdaq: ... of therapeutic and diagnostic products primarily,for disorders in ... Note Purchase Agreement, with Robert Gipson (the "Lender"),pursuant ... aggregate principal amount,of $5,000,000. Pursuant to the Purchase ...
Other Biology Technology:BioSpace Launches the 2008-2009 Pharm Country(TM) Hotbed Campaign 2Indevus Receives Approvable Letter from FDA for NEBIDO(R) 2Indevus Receives Approvable Letter from FDA for NEBIDO(R) 3Indevus Receives Approvable Letter from FDA for NEBIDO(R) 4Indevus Receives Approvable Letter from FDA for NEBIDO(R) 5Indevus Receives Approvable Letter from FDA for NEBIDO(R) 6Indevus Receives Approvable Letter from FDA for NEBIDO(R) 7Alseres Pharmaceuticals, Inc. Raises $5 Million 2Alseres Pharmaceuticals, Inc. Raises $5 Million 3
(Date:12/3/2009)... warmer water, according to an intriguing new study suggesting that ... with two species of young damselfish on Australia,s Great Barrier ... fish are either consistently timid, or consistently bold, and that ... rise. , A slight lift of just one or two ...
(Date:12/3/2009)... the U.S. Department of Energy,s (DOE) Brookhaven National Laboratory, ... made a major step in understanding how molecules locate ... carry out important biological processes. The research, published in ... & Molecular Biology , confirms that many proteins responsible ...
(Date:12/2/2009)... PHILADELPHIA Cigarette smoking and alcohol consumption before head ... risk of death, according to published studies. Now, results ... those who continued these habits after cancer diagnosis. , ... this, many still smoke. In our study, 21 percent ...
Breaking Biology News(10 mins):Fish with attitude: Some like it hot 2Grooving down the helix 2Grooving down the helix 3Head and neck cancer survivors who use alcohol and cigarettes have increased death risk 2NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 1NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 2NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 3NCI renews Fox Chase Penn Ovarian Cancer SPORE grant for a third 5 year term 56283 4To get college students to wash hands requires proper tools attention getting tactics 56279 1To get college students to wash hands requires proper tools attention getting tactics 56279 2Anticancer compound found in American mayapple 9798 1Anticancer compound found in American mayapple 9798 2
... scans are an increasingly used X-ray-based tool for providing a ... of CT scanning to diagnose injury, cancer and other health ... frequently, in some cases unnecessarily" What are the health consequences ... a persons life" , In a Nov. 29, 2007 article ...
... a slight or no advantage to each individual man ... same tribe...an advancement in the standard of morality will ... another. , With these words, Charles Darwin ... individuals behaving for the good of their group, often ...
... powered with glucose derived from biomass is described in ... of Global Energy Issues. The experimental device works by ... power the cell, which produces several hundred millivolts. , ... and managed high-energy crops, are gradually becoming a viable ...
Other Biology News:Columbia researchers: Growth of CT scan use may lead to significant public health problem 2Columbia researchers: Growth of CT scan use may lead to significant public health problem 3Group selection, a theory whose time has come...again 2
Mouse monoclonal [SPM325] to Xanthine Oxidase, prediluted ( Abpromise for all tested applications). Antigen: C terminal 358 amino acid fragment of human xanthine oxidase. Entrez Gene ID: 749...
Rab1A...
Drugs and NO-drug Rat Anti-conjugated Acetyl Salicylic Acid Polyclonal Antibody...
Applications: Beadlyte® assay Stability: 2 years at 4°C (lyophilized) or 6 months at -20°C (rehydrated) ...
Biology Products: